A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis

Bristol-Myers Squibb

Summary

The purpose of this study is to evaluate the drug levels, efficacy, and safety of Deucravacitinib (BMS-986165) in pediatric participants with juvenile psoriatic arthritis.

Eligibility

Age range: 5–17 years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria * Participants must have been diagnosed with Juvenile Psoriatic Arthritis (JPsA). * Participants must have at least three joints that are affected by arthritis. * Participants must have tried at least one type of medicine for JPsA for at least three months, but it didn't work well or caused problems. Exclusion Criteria * Participants must not have been diagnosed with JPsA before 5 years of age. * Participants must not have other types of Juvenile Idiopathic Arthritis (JIA) that aren't JPsA, * Participants must not have a history of chronic eye inflammation (uveitis), or w…

A Phase 3, Multicenter, Double-blind, Placebo-controlled, Randomized Withdrawal Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Deucravacitinib in Children and Adolescents From 5 to Less Than 18 Years of Age With Active Juvenile Psoriatic Arthritis

Summary

Eligibility

Interventions

Locations (47)